-
Self-monitoring strategy reduces postpartum hypertension and cardiac remodelling Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-11-28 Karina Huynh
In women with elevated levels of blood pressure during pregnancy, the use of a physician-guided remote telemonitoring programme during the postpartum period improves BP control, according to findings from the POP-HT trial.
-
A Responsibility to Perpetually Seek Improved Risk Stratification Models: Achieving Data Nirvana J. Am. Coll. Cardiol. (IF 24.0) Pub Date : 2023-11-27 S. Adil Husain
-
Causal Pathway of Alcohol Intake: Stress-Related Neuronal Activity and Cardiovascular Risk J. Am. Coll. Cardiol. (IF 24.0) Pub Date : 2023-11-27 Gopisankar Mohanannair Geethadevi
Abstract not available
-
-
-
Lesion Selection and Optimizing PCI: Intravascular Hemodynamics, Imaging, or Both? J. Am. Coll. Cardiol. (IF 24.0) Pub Date : 2023-11-27 Cindy L. Grines, Allison DuPont
-
Changes in Pulmonary Artery Pressure Late in Life: The Atherosclerosis Risk in Communities (ARIC) Study J. Am. Coll. Cardiol. (IF 24.0) Pub Date : 2023-11-27 Rani Zierath, Brian Claggett, Victoria Arthur, Yimin Yang, Hicham Skali, Kunihiro Matsushita, Dalane Kitzman, Suma Konety, Thomas Mosley, Amil M. Shah
-
Age-Related Changes of Pulmonary Artery Systolic Pressure: Prevention Is Key J. Am. Coll. Cardiol. (IF 24.0) Pub Date : 2023-11-27 Bernhard Haring, Philipp Markwirth, Michael Böhm
-
Systemic Atrioventricular Valve Surgery in Patients With Congenitally Corrected Transposition of the Great Vessels J. Am. Coll. Cardiol. (IF 24.0) Pub Date : 2023-11-27 Ahmed A. Abdelrehim, Elizabeth H. Stephens, William R. Miranda, Austin L. Todd, Heidi M. Connolly, Alexander C. Egbe, Luke J. Burchill, Elena A. Ashikhmina, Joseph A. Dearani
-
Systemic Atrioventricular Valve Regurgitation in Corrected Transposition of the Great Arteries: Where Are We? J. Am. Coll. Cardiol. (IF 24.0) Pub Date : 2023-11-27 Sitaram M. Emani, Pedro J. del Nido
-
Adjusting for Congenital Heart Surgery Risk Using Administrative Data J. Am. Coll. Cardiol. (IF 24.0) Pub Date : 2023-11-27 Natalie Jayaram, Philip Allen, Matthew Hall, Tara Karamlou, Joyce Woo, Sarah Crook, Brett R. Anderson
-
Neuroimaging and Neurodevelopmental Outcomes Among Individuals With Complex Congenital Heart Disease: JACC State-of-the-Art Review J. Am. Coll. Cardiol. (IF 24.0) Pub Date : 2023-11-27 Katelyn Phillips, Bridget Callaghan, Vidya Rajagopalan, Farah Akram, Jane W. Newburger, Nadine A. Kasparian
-
Reporting Extended Follow-Up in Cardiovascular Clinical Trials J. Am. Coll. Cardiol. (IF 24.0) Pub Date : 2023-11-27 Mario Gaudino, Stuart Pocock, Frank Rockhold, Deepak L. Bhatt
Abstract not available
-
Reply: Causal Pathway of Alcohol Intake: Stress-Related Neuronal Activity and Cardiovascular Risk J. Am. Coll. Cardiol. (IF 24.0) Pub Date : 2023-11-27 Kenechukwu Mezue, Shady Abohashem, Michael T. Osborne, Ahmed Tawakol
Abstract not available
-
Aspirin exclusion in patients with an LVAD Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-11-27 Gregory B. Lim
Data from the ARIES-HM3 trial show that excluding aspirin from the antithrombotic regimen in patients with advanced heart failure and a left ventricular assist device reduces the number of bleeding events and does not increase the risk of thromboembolism.
-
Albuminuria in cardiac ATTR amyloidosis: prevalence, progression and prognostic importance Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-11-23 Adam Ioannou, Muhammad U Rauf, Rishi K Patel, Yousuf Razvi, Aldostefano Porcari, Ana Martinez-Naharro, Lucia Venneri, Francesco Bandera, Ruta Virsinskaite, Tushar Kotecha, Dan Knight, Aviva Petrie, Carol Whelan, Ashutosh Wechalekar, Helen Lachmann, Philip N Hawkins, Scott D Solomon, Julian D Gillmore, Marianna Fontana
Transthyretin cardiac amyloidosis (ATTR-CA) is an infiltrative cardiomyopathy that commonly presents with concomitant chronic kidney disease. Albuminuria is common in heart failure and associated with worse outcomes, but its prevalence and relationship to outcome in ATTR-CA remains unclear.
-
Coronary microvascular obstruction and dysfunction in patients with acute myocardial infarction Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-11-24 Mattia Galli, Giampaolo Niccoli, Gianluigi De Maria, Salvatore Brugaletta, Rocco A. Montone, Rocco Vergallo, Stefano Benenati, Giulia Magniani, Domenico D’Amario, Italo Porto, Francesco Burzotta, Antonio Abbate, Dominick J. Angiolillo, Filippo Crea
-
-
Innovative Dual Targeting of the Phosphodiesterase Family and Cyclic GMP Pathway in Heart Failure JACC Heart Fail. (IF 13.0) Pub Date : 2023-11-22 John C. Burnett
-
Reducing Pediatric Heart Failure Readmissions: The Time Is Now JACC Heart Fail. (IF 13.0) Pub Date : 2023-11-22 Lydia K. Wright, Joseph W. Rossano
-
Charting a Course for Atherosclerosis Regression: Shifting the Paradigm J. Am. Coll. Cardiol. (IF 24.0) Pub Date : 2023-11-20 Charles A. German, Michael D. Shapiro
-
Impact of vasodilators on diuretic response in patients with congestive heart failure: a mechanistic trial of cimlanod (BMS-986231) Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-11-21 Pierpaolo Pellicori, John G.F. Cleland, Maria Borentain, Jorg Taubel, Fraser Graham, Javed Khan, Dario Bruzzese, Paul Kessler, John J.V. McMurray, Adriaan A. Voors, Christopher M. O'Connor, John R. Teerlink, G. Michael Felker
Cimlanod is a nitroxyl donor with vasodilator properties.
-
Obesity in Heart Failure with Preserved Ejection Fraction: Insights from the REDUCE LAP-HF II Trial Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-11-21 Sheldon E. Litwin, Jan Komtebedde, Tim Seidler, Barry A. Borlaug, Sebastian Winkler, Scott D. Solomon, Jean-Christophe Eicher, Sula Mazimba, Rami Khawash, Aaron L. Sverdlov, Scott L. Hummel, Heiko Bugger, Florian Boenner, Elke Hoendermis, Maja Cikes, Catherine Demers, Guillherme Silva, Vanessa van Empel, Randall Starling, Martin Penicka, Donald E. Cutlip, Martin B. Leon, Dalane W. Kitzman, Dirk J.
Obesity is causally related to the development of HFpEF but complicates the diagnosis and treatment of this disorder. We aimed to determine the relationship between severity of obesity and clinical, echocardiographic and hemodynamic parameters in a large cohort of patients with documented HFpEF.
-
Rationale and Design of the ESC Heart Failure III Registry – Implementation and Discovery Eur. J. Heart Fail. (IF 18.2) Pub Date : 2023-11-21 Lars H. Lund, Maria Generosa Crespo-Leiro, Cecile Laroche, Jose M. Garcia-Pinilla, Ahmed Bennis, Eleonora B. Vataman, Marija Polovina, Slavica Radovanovic, Svetlana R. Apostolovic, Milika Ašanin, Andrzej Gackowski, Agnieszka Kaplon-Cieslicka, Irina Cabac-Pogorevici, Stefan D. Anker, Ovidiu Chioncel, Andrew J. S. Coats, Gerasimos Filippatos, Mitja Lainscak, Theresa Mcdonagh, Alexandre Mebazaa, Marco
Heart failure outcomes remain poor despite advances in therapy. The European Society of Cardiology (ESC) Heart Failure (HF) III Registry (ESC HF III Registry) aims to characterize HF clinical characteristics and outcomes and to assess implementation of guideline-recommended therapy in Europe and other ESC affiliated countries.
-
SGLT2 Inhibitors in Patients With Cancer Therapy-Related Cardiotoxicity: An Unexpected Benefit? JACC Heart Fail. (IF 13.0) Pub Date : 2023-11-22 Ohad Oren, Pradeep Natarajan, Deepak L. Bhatt
-
Risk Stratification in Advanced Heart Failure: Can Simple Hemodynamic Indices Replace Comprehensive CPET? JACC Heart Fail. (IF 13.0) Pub Date : 2023-11-22 Shweta R. Motiwala, Matthew Nayor
-
Skeletal Muscle Involvement in Patients With Truncations of Titin and Familial Dilated Cardiomyopathy JACC Heart Fail. (IF 13.0) Pub Date : 2023-11-22 Sofie Vinther Skriver, Bjørg Krett, Nanna Scharf Poulsen, Thomas Krag, Helle Rudkjær Walas, Alex Hørby Christensen, Henning Bundgaard, John Vissing, Christoffer Rasmus Vissing
-
Prevalence of Subclinical Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction JACC Heart Fail. (IF 13.0) Pub Date : 2023-11-22 Eunice Yang, Susan R. Heckbert, Jennifer Ding, David Spragg, Hugh Calkins, Sanjiv Shah, Moyses Szklo, Wendy S. Post, Kavita Sharma
-
Effectiveness of Cerebral Embolic Protection in Transcatheter Aortic Valve Replacement with High Aortic Valve Calcium Burden Eur. Heart J. (IF 39.3) Pub Date : 2023-11-23 A Gupta, O Koren, V Patel, T Nagasaki, D Patel, K Golwala, T Chakravarty, H Al-Jilaihawi, M Nakamura, R Makkar
Background The use of a cerebral embolic protection device (CEPD) during transcatheter aortic valve replacement (TAVR) has not been shown to be effective in preventing stroke in the PROTECTED-TAVR randomized controlled trial. However, whether CEPD may specifically benefit patients with high aortic valve calcium burden has not been studied. Purpose This study aimed to determine the effectiveness of
-
Validation of pressure - derived microvascular resistance reserve (MRR) by Doppler wire measurement - the impact of correction for the error of hydrostatic pressure Eur. Heart J. (IF 39.3) Pub Date : 2023-11-22 Z Koszegi, A Dorj, A Agoston, A Uveges, B Tar, M Kest, G T Szabo, D Czuriga
Background The pressure-bounded coronary flow reserve (CFRpb) defines the possible CFR interval (between CFRpbmin and CFRpbmax) using intracoronary pressure data. However, its correlation to the Doppler wire measurement was reported to be poor, partly due to the non-inclusion of the hydrostatic pressure error in the calculations. Microvascular resistance reserve (MRR), a specific index of coronary
-
Predictors of successful post-PCI optimization in vessels with post-PCI fractional flow reserve <0.90: findings from the FFR REACT trial Eur. Heart J. (IF 39.3) Pub Date : 2023-11-22 T Neleman, A C Ziedses Des Plantes, A Scoccia, F T W Groenland, L J C Van Zandvoort, J M R Ligthart, K T Witberg, H Boersma, R J Nuis, W K Den Dekker, R Diletti, J Wilschut, N M Van Mieghem, J Daemen
Introduction Recent studies demonstrated a strong relation between suboptimal post-PCI fractional flow reserve (FFR) and clinical outcome. The feasibility of post-PCI FFR optimization and its impact on future clinical outcome remains topic of debate. Purpose The aim of the present substudy of the FFR REACT trial was to identify predictors of 1) absolute FFR increase following optimization and 2) successful
-
Longitudinal trajectories of lipid parameters and their associations with mid-life carotid intima-media thickness Eur. Heart J. (IF 39.3) Pub Date : 2023-11-22 K Kohansal, A M I R Abdi, S I A M A K Afaghi, F A R Z A D Hadaegh, D A V O O D Khalili
Background/Introduction Studies showed positive associations between previous dyslipidemia and subsequent subclinical atherosclerosis. Purpose To examine the longitudinal association of cumulative burden of different lipid parameters and subsequent carotid intima-media thickness (CIMT). Methods Using data from the Coronary Artery Risk Development in Young Adults (CARDIA) study from year 0 (Y0) to year
-
NT-pro-BNP pre TAVI and relationship with long-term outcomes Eur. Heart J. (IF 39.3) Pub Date : 2023-11-22 L M Soerensen, J K Petersen, J E Strange, M Schou, L Koeber, O De Backer, E Fosbol
Background Blood levels of NT-proBNP correlates with aortic valve stenosis and has been suggested as a future target for intervention or selection of patients for aortic valve replacement. Purpose To examine how levels of NT-proBNP pre-TAVI relates to risk of one-year rates of heart failure admission and mortality in patients undergoing TAVI. Methods With Danish nationwide registries, we identified
-
Deep-learning based analysis of intracoronary optical coherence tomography images: detection and characterization of lipid plaques Eur. Heart J. (IF 39.3) Pub Date : 2023-11-22 R H J A Volleberg, G Rodgriguez Esteban, J H Q Mol, S Quax, I Isgum, C I Sanchez, B Van Ginneken, J Thannhauser, N Van Royen
Background Intracoronary optical coherence tomography (OCT) enables in vivo detection and characterization of atherosclerotic disease. However, manual assessment of OCT images is time-consuming and subject to intra- and interobserver variability. Therefore, automated and trustworthy methods for plaque assessment are warranted. Purpose To develop and validate an artificial intelligence based algorithm
-
Ten years follow-up after aortic valve replacement with bioprosthesis trifecta: a single center retrospective cohort Eur. Heart J. (IF 39.3) Pub Date : 2023-11-22 C Goncalves, R Cerqueira, J Araujo, S Moreira, P Palma, J Almeida, M J Amorim, P Pinho, S O Diaz, A S Barros, A P Lourenco, F Saraiva, A Leite- Moreira
Introduction St. Jude’s Trifecta (TF) bioprosthesis were adopted at most centers due to their unique design and hemodynamic performance. However, concerns regarding durability have been raised and long-term follow-up studies (≥10 years) are scarce. Purpose To report hemodynamic performance as well as early and long-term results of TF valve. Material and Methods In this longitudinal, single-center study
-
Effects of different obesity evaluation indexes on long-term blood pressure variability in adults Eur. Heart J. (IF 39.3) Pub Date : 2023-11-22 R Huang, Z Q Jing, H Y Liu, Z Y Li, S S Wu, D Li, F Zhao, J Hao, C L Yang, J S Song, X Z Gu
Background In recent years, people have a new understanding of the treatment of hypertension. Even at the optimal blood pressure levels recommended by the guidelines, further attention to blood pressure variability is warranted. Obesity and overweight are associated with blood pressure variability, but existing studies mainly focus on the effect of traditional obesity indicators on blood pressure variability
-
Association of hydrochlorothiazide treatment compared to alternative diuretics with overall and skin cancer risk: a propensity-matched cohort study Eur. Heart J. (IF 39.3) Pub Date : 2023-11-22 F Goetzinger, T Wilke, F Hardtstock, J Krieger, U Maywald, M Kunz, L Lauder, M Schulz, F Mahfoud, M Boehm
Introduction Hydrochlorothiazide (HCT) has been suggested to induce photosensitivity, thereby increasing the incidence of skin cancers. After a pharmacovigilance alert, HCT was frequently withdrawn or substituted by other diuretics. The aim of this study was to compare the association of exposure to HCT with cancer risk versus alternative diuretics. Methods A retrospective cohort study was conducted
-
Importance of smooth muscle p110alpha/AKT/FOXO1 signaling for the development of abdominal aortic aneurysm Eur. Heart J. (IF 39.3) Pub Date : 2023-11-22 M Vantler, M Schorscher, E M Berghausen, J B Moore Iv, D Wong, Z Li, L Gnatzy-Feik, M Zierden, D Mehrkens, M Adam, G Sengle, P Boor, L Maegdefessel, S Baldus, S Rosenkranz
Background Abdominal aortic aneurysms (AAA) are characterized by loss of vascular smooth muscle cells (SMCs) and extracellular matrix (ECM) degradation. The catalytic PI 3-kinase isoform p110α signals downstream of growth factor receptors. Mice harboring an SMC-specific p110α deficiency (SM-p110α-/-) are characterized by impaired SMC proliferation and survival. Aim We hypothesized that p110α deficiency
-
Prognostic change of adding coronary calcium score and genetic risk score to European SCORE2 in a moderate risk region Eur. Heart J. (IF 39.3) Pub Date : 2023-11-22 M Temtem, R Palma Dos Reis, M Serrao, M Santos, D Sa, F Sousa, M Rodrigues, S Freitas, E Henriques, S Borges, G Guerra, I Ornelas, A Drumond, A C Sousa, M I Mendonca
Introduction Cardiovascular disease is a public health issue remaining the leading cause of death worldwide. One of its main contributors is coronary artery disease (CAD), a complex multifactorial disease with the influence of hereditary and environmental factors. It’s crucial to improve cardiovascular risk assessment which is a real challenge in our daily clinical practice. SCORE 2 enhanced the identification
-
Feasibility and accuracy of real-time 3D-holographic graft length measurement, a sub-study of the FAST-TRACK CABG trial Eur. Heart J. (IF 39.3) Pub Date : 2023-11-22 T Tsai, S Kageyama, X C He, Y Onuma, G Pompilio, D Andreini, M La Meir, J De Mey, J Puskas, J Narula
Background 3D Hologram is an emerging tool for intuitively manipulating and visualizing CT images. Mixed reality (MR) technology can display high-definition 3D holograms while preserving situational awareness. The new MR software offers the possibility to measure 3D objects using hand gestures and voice commands. However, these measurements made on 3D holograms have not been validated. Purpose We aimed
-
A comprehensive analysis of 30 Biomarkers and their association with cardiovascular outcomes and mortality in the UK Biobank Eur. Heart J. (IF 39.3) Pub Date : 2023-11-22 C J Y Lee, M C Honigberg, S Kany, S H Choi, C Andersson, A W Hall, C Roselli, G Hindy, M Wang, A V Khera, P Natarajan, C Torp-Pedersen, P T Elllinor
Background The use of a comprehensive panel of circulating biomarkers in risk estimation of cardiovascular disease and mortality in a general healthy population remains uncertain. Methods The individual association of 30 clinically available biomarkers with risk of incident heart failure (HF), atrial fibrillation (AF), stroke, myocardial infarction (MI), venous thromboembolism (VTE), and mortality
-
Timing on patent foramen ovale closure: early versus delayed closure Eur. Heart J. (IF 39.3) Pub Date : 2023-11-22 A Jeronimo, L Nombela-Franco, X Freixa, F Tomassini, S Lopez-Tejero, S Ojeda, G Veiga, L Goncalves-Ramirez, S Garcia-Blas, P Salinas
Introduction Pivotal randomized clinical trials showed benefit in patent foramen ovale closure (PFOC) up to 9 months after a cryptogenic stroke or transient ischemic attack (TIA) [1-4]. It might be sensible to indicate PFOC also in non-recent cryptogenic strokes, but evidence is lacking. Purpose We aimed to compare the effectiveness of PFOC according to the time elapsed from the patient’s last episode
-
Treatment of coronary artery disease with sirolimus- versus paclitaxel-coated balloons Eur. Heart J. (IF 39.3) Pub Date : 2023-11-22 F Cuculi, M Madanchi, G M Cioffi, I Majcen, E Gnan, V Gjergjizi, Y Zhi, T Seiler, A Attinger-Toller, M Bossard
Background Percutaneous coronary interventions (PCI) with paclitaxel-coated balloons (PCB) represent an established treatment for in-stent restenosis (ISR) and small coronary arteries. Lately sirolimus-coated balloons (SCB) have been introduced. Yet, studies comparing SCBs to PCBs are lacking. Purpose We sought to assess clinical outcomes at 12 months of an all-comer population presenting with acute
-
Protecting the vulnerable during a crisis - TAVR during the COVID-19 pandemic Eur. Heart J. (IF 39.3) Pub Date : 2023-11-22 A Zaka, N Mridha, J Abtahi, S Anderson, D Murdoch
Introduction The coronavirus (COVID-19) pandemic has been challenging for healthcare systems globally. Patients with symptomatic severe aortic stenosis awaiting transcatheter aortic valve replacement (TAVR) are a vulnerable, elderly subset of patients often with multiple comorbidities. Untreated severe aortic stenosis (AS) is associated with a poor prognosis. It is uncertain if population-based strategies
-
Valve-in-valve transcatheter aortic valve implantation for degenerative stentless versus stented surgical bioprostheses Eur. Heart J. (IF 39.3) Pub Date : 2023-11-22 J Steul, M Abdel-Wahab, T Stankowski, S Haussig, F Woitek, T Gasior, L Crusius, L Knorr, F Mueller, P Kiefer, U Kappert, D Holzhey, A Linke, N Mangner
Introduction Valve-in-valve (ViV) transcatheter aortic valve implantation (TAVI) is a viable and less-invasive alternative to open heart surgery in selected patients with bioprosthetic valve dysfunction. Most ViV-TAVI procedures have been performed in failing stented bioprosthetic valves; stentless bioprostheses lack fluoroscopic markers and could be more challenging for transcatheter therapy. Data
-
Cardiac rehabilitation reduces risk of overall mortality within 12 months after a heart failure hospitalization: data linkage analysis of 9,023 patients in Australia Eur. Heart J. (IF 39.3) Pub Date : 2023-11-22 A Beleigoli, L G Gebremichael, N B Bulamu, K Nesbitt, J S Ramos, J Foote, R A Clark
Background Meta-analyses of randomized trials show that cardiac rehabilitation (CR) prevents cardiovascular (CV) and heart failure (HF)-specific hospitalizations. However, globally only 30-50% of eligible patients participate in CR which might affect CR effectiveness. Purpose To investigate CR utilization and clinical outcomes after an admission for HF. Methods This is a retrospective cohort study
-
Should women have lower thresholds for hypertension? Severe ultrastructural abnormalities in systemic arterioles of normotensive and hypertensive women Eur. Heart J. (IF 39.3) Pub Date : 2023-11-22 L M Brewster, I D Perrotta, Z Taherzadeh, G E R T Van Montfrans
Background Hypertension in women is increasingly recognized to originate in the pre-menopause, but the factors that may affect the greater blood pressure increments observed in premenopausal women compared to age-matched men are understudied. Uterine fibroids, occurring in 30-50% of all women, are a strong sex-specific factor associated with hypertension and early cardiovascular events, but the nature
-
Associations of long-term visit-to-visit blood pressure variability with subclinical kidney damage and albuminuria in adulthood: a 30-year prospective cohort study Eur. Heart J. (IF 39.3) Pub Date : 2023-11-22 Y Wang, P Zhao, C Chu, M F Du, X Y Zhang, T Zou, G L Hu, H Jia, Y Y Liao, Q Ma, D Wang, F Y Chen, J J Mu
Background Recent evidence indicates that long-term visit-to-visit blood pressure variability (BPV) may be associated with the risk of cardiovascular disease. We therefore aimed to determine the potential associations of long-term BPV from childhood to middle age with subclinical kidney damage (SKD) and albuminuria in adulthood. Methods Using data from the ongoing cohort of Hanzhong Adolescent Hypertension
-
Sex specific lifetime risk of incident cardiovascular events. Results from a large British population-based cohort study Eur. Heart J. (IF 39.3) Pub Date : 2023-11-22 T A Pana, M A Mamas, N J Wareham, K T Khaw, D K Dawson, P K Myint
Background There are marked sex differences in cardiovascular (CV) disease, most characteristically with men having a higher risk of coronary heart disease and myocardial infarction (MI). The sex differences in the absolute lifetime risk of CV disease as well as the different profiles of first incident CV events remain poorly described. Purpose Using data from a large British population-based cohort
-
Very long-term prognostic value of clinical SYNTAX score in patients undergoing percutaneous coronary intervention for left main coronary artery disease Eur. Heart J. (IF 39.3) Pub Date : 2023-11-22 J Lee, M Jung, H Kwak, E Chang, J Jung, E Rhee, Y Park, B Park, H Kim, N Kim, S Jang, M Bae, D Yang, H Park, Y Cho
Background Recently, long-term prognostic value of SYNTAX score (SS) has been validated in patients with left main coronary artery disease (LMCA). However, the ability of clinical SYNTAX score (CSS) to predict very long-term outcomes in patients undergoing percutaneous coronary intervention (PCI) for LMCA has not been fully investigated yet. Purpose We aimed to validate the impact of CSS on very long-term
-
Impact of atrial fibrillation type on outcomes following aerobic exercise training: analysis from the ACTIVE-AF Trial Eur. Heart J. (IF 39.3) Pub Date : 2023-11-22 A Elliott, C V Verdicchio, R Mahajan, C Gallagher, D H Lau, M E Middeldorp, P Sanders
Background The ACTIVE-AF study demonstrated that aerobic exercise prescription promotes the maintenance of sinus rhythm in patients with atrial fibrillation (AF). However, it is unclear whether these benefits are observed in patients with both paroxysmal and persistent AF. Purpose Compare efficacy of exercise intervention on arrhythmia recurrence between paroxysmal (ParAF) and persistent (PerAF) patients
-
Blood pressure variability as a prognostic factor in patients with acute myocardial infarction. Data from the ACS-BP study Eur. Heart J. (IF 39.3) Pub Date : 2023-11-22 K Konstantinou, A Koumeli, A Apostolos, K Dimitriadis, A Sakalidis, K Papelis, C Fragoulis, M Mantzouranis, S Vaina, K Tsioufis
Background Blood pressure variability (BPV) is considered a modern cardiovascular risk factor. There are many data relating BPV to mortality, risk of stroke and target organs damage mainly in hypertensive patients. Purpose The purpose of the present study is to investigate whether BPV in patients with acute myocardial infarction (AMI) who all underwent percutaneous coronary intervention (PCI) was associated
-
The role of preparticipation screening in detecting silent coronary artery disease in master athletes: a way to prevent exercise-related adverse cardiovascular events Eur. Heart J. (IF 39.3) Pub Date : 2023-11-22 G Scarfo', A Rizza, J Fusi, L Besola, A Colli, F Franzoni
Introduction Regular exercise reduces morbidity and mortality from cardiovascular diseases through cardiac and systemic adaptations including the increased coronary blood flow, an improved endothelial function, a slower progression of atherosclerotic processes as well as the stabilization of pre-existing lesions. However, long-term exercise is frequently associated with adverse cardiovascular events
-
Genetic predisposition to high blood pressure and out-of-office hypertension: insights from a population sample in Liechtenstein Eur. Heart J. (IF 39.3) Pub Date : 2023-11-22 S Narula, P M Mohammadi-Shemirani, S Aeschbacher, M R Chong, A Le, S Theriault, K Grossman, G Pare, L Risch, M Risch, D Conen
Genetic predisposition is a risk factor for office hypertension. We tested whether genetic background could identify individuals with ambulatory daytime hypertension in a sample of white Europeans from Liechtenstein. We evaluated two measures of predisposition to hypertension: family history and polygenic risk scores (PRS). Our analytic sample contained 1444 participants aged 25 to 41. 12% of participants
-
Evening anti-hypertensive dosing, blood pressure and cardiovascular events in hypertensive: Updated meta-analysis of 41 trials in 65,271 patients Eur. Heart J. (IF 39.3) Pub Date : 2023-11-22 A F Sunjaya, A P Sunjaya
Introduction In 2022, the International Society of Hypertension and World Hypertension League released a position paper noting that there is limited evidence on the impact of bedtime versus other time dosing of antihypertensives on 24-h BP profile and on cardiovascular morbidity and mortality. Since then, the Treatment In Morning versus Evening (TIME) trial results which enrolled over 20 thousand participants
-
Lipids, lipoproteins, and apolipoproteins during the first year of life: a prospective cohort study Eur. Heart J. (IF 39.3) Pub Date : 2023-11-22 S T Nielsen, R M Lytsen, N Strandkjaer, I J Rasmussen, A S Sillesen, R O Voegg, A R Axelsson, B G Nordestgaard, P R Kamstrup, K K Iversen, H Bundgaard, A Tybjaerg-Hansen, R Frikke-Schmidt
Background/Introduction Cardiovascular disease (CVD) is the leading cause of morbidity and mortality globally, and treatment of well-established lifestyle risk factors are cornerstones in CVD prevention. An atherogenic lipid profile with high concentrations of low-density lipoprotein (LDL) cholesterol and other apolipoprotein B containing lipoproteins is a driving force in the pathogenesis of atherosclerotic
-
Modifiable risk factors and inflammatory burden stratified by the presence and extent of atherosclerotic cardiovascular disease: insights from a population based cohort study Eur. Heart J. (IF 39.3) Pub Date : 2023-11-22 B Bay, C Blaum, C Kellner, R Bei Der Kellen, F Ojeda, J Waibel, N Arnold, C A Behrendt, B Zyriax, D L Rimmele, R Twerenbold, S Blankenberg, F J Brunner, C Waldeyer
Background/Introduction Inflammation is recognized as a residual risk factor and mediator in patients with Atherosclerotic Cardiovascular Disease (ASCVD). High-sensitivity C-Reactive Protein (hsCRP), a marker of systemic inflammation, can be affected by modifiable risk factors (modRF). On the other hand, ASCVD and its extent might modify hsCRP levels. Data regarding the relationship between hsCRP,
-
Improved health-related quality of life after renal denervation in patients with resistant hypertension: 3-year outcomes in the global symplicity registry Eur. Heart J. (IF 39.3) Pub Date : 2023-11-22 F Mahfoud, J Weil, G Mancia, R E Schmieder, L Ruilope, M Schlaich, K Narkiewicz, B Williams, M Fahy, M Bohm
Background Hypertension is associated with increased mental anxiety and depression. Renal denervation (RDN) reduces blood pressure (BP) in patients with uncontrolled, resistant hypertension (rHTN). The Global SYMPLICITY Registry (GSR) DEFINE is a prospective, open-label, single-arm, all-comer worldwide study, enrolling patients to undergo RDN. Whether BP reductions after RDN improve patients’ self-reported
-
Impact of age versus comorbidities on outcomes after transcatheter aortic valve implantation: validating the guideline-recommended age cut-off Eur. Heart J. (IF 39.3) Pub Date : 2023-11-22 L Hannen, S Ludwig, C Kellner, D Grundmann, T Demal, L Waldschmidt, L Voigtlaender-Buschmann, M Linder, P Kirchhof, L Conradi, H Reichenspurner, S Blankenberg, A Schaefer, M Seiffert, N Schofer
Background Transcatheter aortic valve implantation (TAVI) has become the most common treatment for patients with severe aortic stenosis (AS) in Europe and North America. Current European guidelines recommend transfemoral TAVI for patients with severe, symptomatic AS aged ≥75 years. However, this cut-off is based solely on coincidentally existing patient cohort mean age of randomized controlled trials
-
Adherence to ESC guidelines for antihypertensive drug therapy: real-world survey from an EU country Eur. Heart J. (IF 39.3) Pub Date : 2023-11-22 M Selvek, K Vallova, R Muzik, H Tulejova, P Istokovicova, I Tkac, R Hatala
Background Achieving optimal BP control in hypertensive patients (pts) remains a continuous challenge worldwide. Multiple factors are responsible for the low rates of BP control with suboptimal drug choice playing a key role. Practice guidelines should serve as evidence based foundation for optimal antihypertensive drug therapy but their impact in the real-world is variable. Purpose This retrospective